Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Staphylococcal Infection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

NCT01769417
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Placebo, MEDI4893
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures

NCT05090657
View directory record Official record
Conditions
Surgical Site Infections, Nosocomial Infection, Healthcare Associated Infections
Interventions
methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
Combination Product
Lead sponsor
Ondine Biomedical Inc.
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

NCT01827358
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees

NCT01105767
View directory record Official record
Conditions
Staphylococcus Aureus, MRSA Skin Infections, Staphylococcal Skin Infections
Interventions
Chlorhexidine gluconate, Supplemental training, education and hygiene
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 42 Years · Male only
Enrollment
30,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 26, 2026, 9:33 AM EDT
Terminated No phase listed Observational

Impact of Mupirocin Decolonization on the Nasal Microbiome

NCT02045329
View directory record Official record
Conditions
Nasal Colonization With Staph Aureus
Interventions
Not listed
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I STEBVax in Healthy Adults

NCT00974935
View directory record Official record
Conditions
Toxic Shock Syndrome Staphylococcal
Interventions
Aluminum hydroxide, STEBVax vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Red Light Photobiomodulation and Topical Disinfectants

NCT05797818
View directory record Official record
Conditions
Healthcare Associated Infection, Nosocomial Infection, Surgical Site Infection
Interventions
Methylene Blue Only, Chlorhexidine Gluconate Only, Methylene Blue + Chlorhexidine Gluconate, Light Only
Device
Lead sponsor
Ondine Biomedical Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess

NCT02334384
View directory record Official record
Conditions
Furunculosis
Interventions
Antimicrobial TheraGauze
Biological
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

NCT01728363
View directory record Official record
Conditions
Systemic Infection
Interventions
Antibiotic
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
14 Days to 32 Weeks
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

NCT01592214
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Placebo, XF-73 in 2% Klucel gel, XF-73 in 4% Klucel gel
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Anaheim, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Results available

Mupirocin-Iodophor ICU Decolonization Swap Out Trial

NCT03140423
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization
Drug
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
Not listed
Enrollment
353,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
137
States / cities
Riverside, California • San Jose, California • Thousand Oaks, California + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 26, 2026, 9:33 AM EDT
Terminated Not applicable Interventional

Targeted Gown and Glove Intervention in Nursing Homes

NCT04200508
View directory record Official record
Conditions
Staphylococcus Aureus, Carbapenem Resistant Gram Negative Bacteria
Interventions
Targeted gown and gloves use
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU

NCT02967432
View directory record Official record
Conditions
Staphylococcus
Interventions
Mupirocin Topical Ointment, Petroleum Jelly
Drug
Lead sponsor
Crouse Hospital
Other
Eligibility
Not listed
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 26, 2026, 9:33 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 26, 2026, 9:33 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues

NCT04666532
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 26, 2026, 9:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

NCT00859677
View directory record Official record
Conditions
HIV Infections, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
2
States / cities
San Diego, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

NCT00631566
View directory record Official record
Conditions
HIV Infections, Staphylococcal Infections
Interventions
Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
4
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 4 Interventional

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

NCT00304811
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Vancomycin, Vancomycin plus Gentamicin, Vancomycin plus Rifampin, Vancomycin plus Gentamicin plus Rifampin
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2009 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
NDV-3A, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
17 Years to 35 Years · Male only
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Benning, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

NCT01447407
View directory record Official record
Conditions
Staphylococcal Infections, Yeast Infections, Candidiasis
Interventions
NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM, NDV-3 vaccine without alum ID
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

S. Aureus Screening and Decolonization

NCT02182115
View directory record Official record
Conditions
Wound Infection Due to Staphylococcus Aureus, MRSA Infection of Postoperative Wound
Interventions
antiseptic bundle, standard of care
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879
View directory record Official record
Conditions
Infection, Bacteremia
Interventions
Telavancin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)

NCT01589185
View directory record Official record
Conditions
Pneumonia Due to Staphylococcus Aureus
Interventions
KBSA301, Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

NCT01643941
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, SA4Ag vaccine high dose, SA3Ag vaccine, Blood sample, Placebo, Colonization swab samples
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 26, 2026, 9:33 AM EDT